Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma (MEL37)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00912418
Recruitment Status : Completed
First Posted : June 3, 2009
Last Update Posted : June 19, 2013
Information provided by (Responsible Party):
University of Virginia

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : No date given
  Study Completion Date : No date given